Skip to main content
. 2022 Feb 2;43(9):2429–2438. doi: 10.1038/s41401-021-00855-6

Fig. 3. HT-15 exerts anti-inflammation effects in vitro and potentially reduces the side effects caused by GCs.

Fig. 3

a Venn diagrams of genes regulated by HT-15 and Dex in LPS (20 ng/mL) stimulated RAW264.7 cells and the gene expression profile of commonly induced or repressed genes by both HT-15 and Dex (n = 3). b Validation of the repressed genes (IL-1β, IL-6, TNF-ɑ, CCL-2, CSF-2, SOCS3, and COX-2) of HT-15 by Q-PCR and the effects of HT-15 on FKBP5 mRNA expression in RAW264.7 cells (n = 5). Values are presented as mean ± SD. *P < 0.05 versus LPS stimulated group. c The effect of HT-15 on the mRNA expressions of IL-1β, IL-6, COX-2 and FKBP5 in PMA-stimulated A549 cells (n = 5). Values are presented as mean ± SD. *P < 0.05 versus PMA-stimulated group. d–f An examination of the off-target effects by the reporter assays for AR, PR and MR (n = 4). g–i The influence of HT-15 on the mRNA expressions of OPG and RANKL (n = 5). *P < 0.05 versus DMSO treated group.